

Analytical and clinical evaluation of four anti-SARS-CoV-2 serologic (IgM, IgG, and total) immunoassays

Victoria Higgins^a, Anselmo Fabros^b, Xiao Yan Wang^b, Maria Bhandari^c, David J. Daghfal^c,
Vathany Kulasingam^{a,b#}

^aDepartment of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada

^bDepartment of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada

^cAbbott Diagnostics, Lake Forest, Illinois, USA

Running Title: Evaluation of four anti-SARS-CoV-2 serologic assays

#Corresponding Author:

Vathany Kulasingam, PhD, FCACB

Laboratory Medicine Program, University Health Network

200 Elizabeth Street, Room 3 EB 362C

Toronto, ON M5G 2C4

Phone: 416-340-4800 ext. 8589

Email: vathany.kulasingam@uhn.ca

1 **Abstract**

2 **Introduction**

3 Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
4 coronavirus 2 (SARS-CoV-2), is diagnosed by molecular-based detection of SARS-CoV-2 RNA.
5 Serologic testing detects antibodies specific to SARS-CoV-2 and IgM specifically may serve as
6 an adjunct test to PCR early in disease. We evaluated the Abbott anti-SARS-CoV-2 IgM and IgG
7 assays along with DiaSorin anti-SARS-CoV-2 IgG and Roche anti-SARS-CoV-2 Total.

8 **Methods**

9 Specimens from 175 PCR-positive patients and 107 control specimens were analyzed using
10 Abbott IgM and IgG, DiaSorin IgG, and Roche Total (IgA, IgG, IgM) assays. Sensitivity,
11 specificity, cross-reactivity, concordance between assays, trends over time, positive predictive
12 value (PPV), and negative predictive value (NPV) were determined.

13 **Results**

14 Abbott IgM sensitivity was 63.6% at 0 days post-PCR positivity, 76.5% at 1-5d, 76.3% at 6-14d,
15 85.2% at 15-30d, and 63.6% at >30d. All assays exhibited highest sensitivity 15-30d post-PCR
16 positivity (83.3-85.2%). Combining Abbott IgM and IgG improved sensitivity by 22.7%
17 compared to IgG alone when tested 0d post-PCR positivity. All assays had a specificity of 100%
18 and only Abbott IgG exhibited cross-reactivity (anti-dsDNA). Cohen's kappa varied between
19 0.86-0.93. Time to seroconversion from PCR positivity was lowest for Abbott IgM and highest
20 for Abbott IgG. NPV was highest for Abbott IgM <14 days post-PCR positivity and Abbott IgG
21 ≥ 14 days.

22 **Conclusion**

23 The Abbott IgM assay exhibited the earliest response and greatest signal in most patients
24 evaluated for serial sampling and had the highest NPV <14 days post-PCR positivity, suggesting
25 its potential utility as an adjunct test to PCR early in disease course.

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46 **Introduction**

47 Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome
48 coronavirus 2 (SARS-CoV-2), emerged from Wuhan, China in late 2019 (1). COVID-19 was
49 first declared a Public Health Emergency of International Concern in January 2020 by the World
50 Health Organization (WHO) and has infected over 37 million people globally, causing over one
51 million deaths as of 11 October 2020 (2). Clinical manifestations of COVID-19 illness vary in
52 severity between patients from asymptomatic to severe pneumonia, acute respiratory distress
53 syndrome, sepsis, and/or multisystem organ failure (3). COVID-19 is diagnosed by molecular-
54 based detection of SARS-CoV-2 RNA, most commonly by reverse transcription-polymerase
55 chain reaction (RT-PCR) in nasopharyngeal and/or oropharyngeal specimens (4). Viral RNA can
56 be detected in these specimens as early as the first day of symptom onset, peaks within the first
57 week, and can remain positive beyond three weeks in severe cases (5,6). However, PCR
58 positivity only reflects viral RNA detection, not necessarily the presence of viable virus (7), and
59 its predictive value varies with time from exposure and symptom onset (8). For example, one
60 study reported the probability of a false negative result to be 100% on day 1 of infection, 67% on
61 day 4, 38% on day 5 (symptom onset), 20% on day 8, and 66% on day 21 (8).

62 Serologic testing detects antibodies (e.g. IgG, IgM) specific to SARS-CoV-2 in blood,
63 serum, or plasma. While serologic testing is not useful on its own for COVID-19 diagnosis (9), it
64 may serve as an adjunct to molecular-based testing for COVID-19 diagnosis if used ≥ 15 days
65 after symptom onset in cases with suggestive clinical presentation, but where RT-PCR results are
66 negative or not available (9). As IgM is a marker of acute infection, it may be a useful tool to
67 combine with PCR to improve sensitivity and specificity early in the disease course (i.e. < 14
68 days after symptom onset) (10–12). Antibody response has been reported to correlate with

69 disease severity, with more severe cases exhibiting immediate seroconversion (13). Furthermore,
70 antibody titers were found to be higher in severe compared to non-severe cases two weeks post-
71 symptom onset (12). Serologic testing may also have clinical utility for surveying asymptomatic
72 infection in close contacts and population-level assessment of the prevalence of past SARS-CoV-
73 2 infection (12,14,15). While data are still limited, there is mounting evidence that antibodies
74 detected by commercial serologic assays correlate with neutralization capacity (16) and confer
75 some resistance to re-infection (17,18). Thus, serologic testing may also have clinical utility for
76 international travel authorization, assessing reinfection risk in workplaces, and facilitating
77 economic activity resumption.

78 In order to demonstrate an adequate positive predictive value, it is important for serologic
79 assays to demonstrate high sensitivity and specificity, particularly when seroprevalence is low
80 (19). It has been suggested that laboratories should implement SARS-CoV-2 serologic tests that
81 have manufacturer-claimed sensitivity $\geq 95\%$ and specificity $\geq 99.5\%$ based on specimens
82 obtained ≥ 14 days after symptom onset or PCR positivity (20). We evaluated the sensitivity,
83 specificity, cross-reactivity, concordance, trends over time, positive predictive value, and
84 negative predictive value for four serologic assays: Abbott anti-SARS-CoV-2 IgM serologic
85 assay, Abbott anti-SARS-CoV-2 IgG, DiaSorin anti-SARS-CoV-2 IgG, and Roche anti-SARS-
86 CoV-2 Total assays.

87 **Materials and Methods**

88 *Sample Collection and Analysis*

89 This work was exempt from Quality Improvement (QI) review and Research Ethics
90 Board (REB) approval at the University Health Network (UHN; Toronto, Canada). Presence or
91 absence of SARS-CoV-2 infections was determined by SARS-CoV-2 viral RNA detection in

92 nasopharyngeal swabs tested at UHN microbiology lab on assays validated for clinical use
93 (Seegene Allplex 2019-nCoV assay which has been approved by Health Canada for Emergency
94 Use Authorization and verified by UHM microbiology lab). Deidentified residual patient serum
95 and plasma samples were collected from UHN and analyzed using four anti-SARS-CoV-2
96 serologic assays at UHN, including SARS-CoV-2 IgG and SARS-CoV-2 IgM on the Abbott
97 ARCHITECT® i (Abbott Diagnostics), SARS-CoV-2 S1/S2 IgG on the LIAISON® XL
98 (DiaSorin), and Elecsys® anti-SARS-CoV-2 total (IgA, IgG, IgM) on the cobas e411 (Roche
99 Diagnostics). Details and performance characteristics of these four serologic assays are described
100 in **Table S1**. The Abbott anti-SARS-CoV-2 IgG and IgM assays are qualitative
101 chemiluminescent microparticle immunoassays (CMIA). The anti-SARS-CoV-2 IgG assay
102 detects IgG antibodies to the nucleocapsid protein of SARS-CoV-2, while the anti-SARS-CoV-2
103 IgM assay detects IgM antibodies to the receptor-binding domain (RBD) of the spike protein
104 (S1) of SARS-CoV-2. The DiaSorin anti-SARS-CoV-2 S1/S2 IgG assay is a qualitative
105 chemiluminescent immunoassay (CLIA) that detects IgG antibodies against the spike protein (S1
106 and S2 subunits) of SARS-CoV-2. Lastly, the Roche anti-SARS-CoV-2 total assay is a
107 qualitative electrochemiluminescence immunoassay (ECLIA) that detects IgA, IgM and IgG
108 antibodies to the nucleocapsid protein of SARS-CoV-2. Preventative maintenance, function
109 checks, calibration, and internal quality control were performed according to the manufacturer's
110 instructions.

111 *Sensitivity*

112 To determine the sensitivity of four anti-SARS-CoV-2 antibody assays, serum or plasma
113 samples were collected from 175 patients that were confirmed positive for SARS-CoV-2
114 infection by PCR testing within the previous 0-73 days. Sensitivity was calculated as true

115 positive / (true positive + false negative), where true positivity was defined as PCR positivity.

116 Total sensitivity and sensitivity for various categories of days post-PCR positivity were
117 determined.

118 *Cross-reactivity & specificity*

119 To determine the cross-reactivity of the four anti-SARS-CoV-2 antibody assays, serum or
120 plasma samples were collected from 107 patients that were positive for viruses other than SARS-
121 CoV-2 (e.g. hepatitis A, hepatitis B, hepatitis C, human immunodeficiency virus, rubella,
122 Epstein-Barr virus, cytomegalovirus, respiratory syncytial virus, enterovirus, rhinovirus,
123 influenza A, influenza B, metapneumovirus, BK virus), had autoantibodies or a known
124 autoimmune condition (e.g. anti-dsDNA, rheumatoid factor, anti-centromere, anti-SSA, anti-Sm,
125 anti-SmRNP, anti-RiboP, celiac disease, anti-MPO, anti-PR3, anti-CCP, antinuclear antibodies),
126 had elevations of other analytes (e.g. creatinine, C-reactive protein, IgA, IgG, IgM), or had the
127 influenza vaccine in 2019. The percentage of samples that were incorrectly identified as positive
128 for SARS-CoV-2 antibodies was determined for each assay.

129 Specificity was assessed using 52 of these samples that were collected from patients in
130 2019, before SARS-CoV-2 was thought to be circulating in Ontario, Canada (n=32), or were
131 confirmed to be SARS-CoV-2 negative by PCR (n=20). Specificity was calculated as true
132 negative / (true negative + false positive), where true negativity was defined as negative by PCR
133 or sample collection prior to the circulation of SARS-CoV-2.

134 *Concordance*

135 Concordance between the four anti-SARS-CoV-2 antibody assays was determined using
136 all 175 samples from the sensitivity analysis and all 107 samples from the cross-reactivity and

137 specificity analysis. Overall percent agreement, positive percent agreement (PPA), negative
138 percent agreement (NPA), and Cohen's kappa were calculated for each pair-wise comparison.

139 *Serial sampling to model antibody response*

140 Serial serum and plasma samples (n=6-20) were collected from five patients that were
141 positive for SARS-CoV-2 by PCR. Data was expressed as a ratio of the response (i.e. assay
142 signal) to the positivity cut-off of the assay. This ratio was examined over time since PCR
143 positivity.

144 *Positive predictive value and negative predictive value*

145 Sensitivity for <14 days and ≥ 14 days post-PCR positivity, as well as specificity for each
146 of the four anti-SARS-CoV-2 serologic assays as determined in this study were used to estimate
147 the positive predictive value (PPV) and negative predictive value (NPV) at seroprevalence values
148 of 1%, 5%, and 10%.

149 **Results**

150 *Sensitivity*

151 **Fig. 1** shows anti-SARS-CoV-2 antibody results for four SARS-CoV-2 serologic assays
152 plotted against days since PCR positivity. Overall, the assay signal does not correlate with days
153 since PCR positivity, with a wide range of signal results observed across all days since PCR
154 positivity.

155 Anti-SARS-CoV-2 antibody sensitivity of four SARS-CoV-2 serologic assays is
156 summarized in **Table 1** and **Fig. 2**. The total sensitivity (independent of days since PCR
157 positivity) ranged from 69.0% to 74.9% across assays. All assays exhibited greater sensitivity
158 ≥ 14 days post-PCR positivity (76.5%-82.4%) compared to <14 days (52.1%-64.4%), although
159 Abbott anti-SARS-CoV-2 IgM exhibited the greatest sensitivity among the assays <14 days. All

160 assays exhibited the highest sensitivity between 15-30 days post-PCR positivity, ranging from
161 83.3% to 85.2%,. As expected, the lowest sensitivity was observed for samples collected the
162 same day as PCR positivity, ranging from 38.1% to 63.6% with the highest sensitivity observed
163 for Abbott anti-SARS-CoV-2 IgM. Overall, 20.6% of patients positive for SARS-CoV-2 by PCR
164 were negative across all four serologic assays, in-line with the large immunocompromised
165 population at UHN.

166 When including both Abbott anti-SARS-CoV-2 IgG and IgM assays, total sensitivity
167 improved from 74.9% (IgG alone) and 74.3% (IgM alone) to 77.7%, as shown in **Table 2** and
168 **Fig. 2**. IgG measurement improved sensitivity for samples >30 days after PCR positivity (13.6%
169 were positive for IgG only). On the other hand, IgM measurement improved sensitivity for
170 samples collected the same day as PCR positivity (22.7% were positive for IgM only).

171 *Cross-reactivity & specificity*

172 Of the 107 control patient samples measured, all were negative for Abbott anti-SARS-
173 CoV-2 IgM, DiaSorin anti-SARS-CoV-2 IgG, and Roche anti-SARS-CoV-2 total. One sample
174 positive for anti-dsDNA antibody (157 IU/mL as measured on the Bioplex 2200 platform) was
175 positive for Abbott anti-SARS-CoV-2 IgG with an index value of 3.49 (positive: ≥ 1.4). Four
176 additional samples positive for anti-dsDNA antibody (concentrations ranging from 19-44 IU/mL)
177 were negative for anti-SARS-CoV-2 antibodies by all four assays. All 52 control patient samples
178 that were collected pre-COVID-19 or were PCR negative were negative by all four serologic
179 assays. Therefore, all four serologic assays exhibited an assay specificity of 100%.

180 *Concordance*

181 **Table 3** and **Fig. S1-S2** summarize the concordance between the four serologic assays.
182 The overall percent agreement and Cohen's kappa varied between 93.2-96.4% and 0.86-0.93,

183 respectively. PPA and NPA varied between 89.1-96.7% and 93.1-99.3%, respectively. The
184 strongest overall percent agreement and Cohen's kappa were observed between Abbott anti-
185 SARS-CoV-2 IgG and Roche anti-SARS-CoV-2 total, which both target the nucleocapsid
186 protein of SARS-CoV-2. The weakest overall percent agreement and Cohen's kappa were
187 observed between Abbott anti-SARS-CoV-2 IgM and DiaSorin anti-SARS-CoV-2 IgG. This was
188 the result of a low PPA (89.1%) due to 14 results positive by Abbott anti-SARS-CoV-2 IgM, but
189 negative by DiaSorin anti-SARS-CoV-2 IgG.

190 *Serial sampling to model antibody response*

191 Trends in anti-SARS-CoV-2 antibody levels over time since PCR positivity, as measured
192 by four serologic assays, are shown in **Fig. 3-7**. It is evident that the antibody response to SARS-
193 CoV-2 infection varies between individual patients and across serologic assay platforms and
194 isotypes. Patients 1 and 2 (**Fig. 3-4**), exhibited a rapid rise in Abbott anti-SARS-CoV-2 IgM
195 levels, reaching a response 60 times the positivity cut-off for the assay and either plateaued
196 (Patient 1) or decreased (Patient 2) around one week post-PCR positivity. All other assays
197 exhibited a lower response that either gradually increased or plateaued around five days post-
198 PCR positivity. Patient 3 (**Fig. 5**) exhibited the greatest response for Roche anti-SARS-CoV-2
199 total, reaching over 60 times the positivity cut-off for the assay and plateauing around 35 days
200 post-PCR positivity, while the other assays exhibited a lower response. Patients 4 and 5 (**Fig. 6-**
201 **7**) exhibited the most rapid response in Abbott anti-SARS-CoV-2 IgM, peaking around day 12
202 post-PCR positivity and subsequently decreasing. Both patients exhibited a delayed response for
203 Roche anti-SARS-CoV-2 total, which subsequently peaked around 40 times the positivity cut-off
204 between 30-45 days post-PCR positivity.

205 **Table 4** summarizes days from PCR positivity to seroconversion as determined for each
206 serologic assay. Overall, the time to seroconversion was lowest for Abbott anti-SARS-CoV-2
207 IgM (median: 0 days; mean: 2.2 days), followed by Roche anti-SARS-CoV-2 total, which also
208 contains IgM (median: 2 days; mean: 3.2 days). Abbott anti-SARS-CoV-2 IgG (median: 3 days;
209 mean: 5.2 days) and DiaSorin anti-SARS-CoV-2 IgG (median: 3 days; mean: 4.8 days) exhibited
210 longer times to seroconversion.

211 *Positive predictive value and negative predictive value*

212 PPV and NPV for the four serologic assays across different seroprevalence estimates
213 (1%, 5%, 10%) <14 days post-PCR positivity and ≥ 14 days are shown in **Table 5**. PPV for all
214 four serologic assays was 100% across all seroprevalence estimates due to the specificity of
215 100% determined in this study. The NPV across all assays was higher for samples collected ≥ 14
216 days post-PCR positivity compared to <14 days, ranging from 97.7%-99.8% and 95.4%-99.7%,
217 respectively. Notably, NPV decreased with increasing seroprevalence.

218 **Discussion**

219 Here, we report analytical and clinical performance characteristics of the Abbott anti-
220 SARS-CoV-2 IgM assay, which is not yet Health Canada approved but has received FDA EUA,
221 alongside three other serologic assays: Abbott anti-SARS-CoV-2 IgG, DiaSorin anti-SARS-
222 CoV-2 IgG, and Roche anti-SARS-CoV-2 Total. For the Abbott anti-SARS-CoV-2 IgM assay,
223 sensitivity was 71.2% and 76.5% for <14 days and ≥ 14 days post-PCR positivity, respectively,
224 with the highest sensitivity (87.5%) between 15-30 days post-PCR positivity. Combining Abbott
225 anti-SARS-CoV-2 IgM and IgG testing improved sensitivity by 22.7% compared to anti-SARS-
226 CoV-2 IgG testing alone, when tested the same day as PCR positivity. Specificity was 100% for
227 all four serologic assays and only Abbott anti-SARS-CoV-2 IgG exhibited cross-reactivity for a

228 sample positive for anti-dsDNA. Trends in anti-SARS-CoV-2 IgM over time since PCR
229 positivity revealed heterogeneity across five patients, although confirming earlier IgM positivity
230 compared to IgG in most patients.

231 Chemiluminescent anti-SARS-CoV-2 serologic assays, as used in this study, have been
232 reported to exhibit high sensitivity, as summarized in a systematic review and meta-analysis
233 (21). The highest pooled sensitivity for anti-SARS-CoV-2 serologic assays was observed for
234 chemiluminescent assays (i.e. 97.8%), followed by enzyme-linked immunosorbent assays
235 (84.3%) and lateral flow immunoassays (66.0%) (21), the latter most commonly used in point-of-
236 care testing systems. Furthermore, anti-SARS-CoV-2 antibodies were reported to have higher
237 pooled sensitivity at least three weeks after symptom onset compared to the first week and there
238 was no association between immunoglobulin class and pooled sensitivity or specificity (21). The
239 higher overall pooled sensitivity reported in this systematic review and meta-analysis compared
240 to our study is likely due to its higher combined sample size of over 29,000 tests and the fact that
241 60% of our samples were analyzed within three weeks of PCR positivity. Perkmann, et al. also
242 evaluated Abbott anti-SARS-CoV-2 IgG, DiaSorin anti-SARS-CoV-2 IgG, and Roche anti-
243 SARS-CoV-2 total and reported sensitivities more similar to those observed in our study, ranging
244 from 83.1% to 89.2% in 65 samples from COVID-19 patients evaluated ≥ 14 days after symptom
245 onset (22). However, as is apparent in our study and others (10,23), sensitivity of the different
246 immunoglobulin classes differ depending on days post symptom onset or PCR positivity.

247 As IgM is a marker of acute infection, anti-SARS-CoV-2 IgM sensitivity has been
248 reported to be higher between 8-14 days (94.4%) compared to ≥ 15 days (89.5%), likely
249 reflecting antibody class switching (24). While PCR sensitivity was higher than anti-SARS-CoV-
250 2 IgM ELISA before 5.5 days post-symptom onset, IgM sensitivity was higher than PCR after

251 5.5 days post-symptom onset (10). Overall, sensitivity increased from 51.9% to 98.6% when
252 testing PCR-negative patients with IgM ELISA compared to PCR testing alone (10), supporting
253 its potential use as an adjunct test for early diagnosis of COVID-19. While we did not compare
254 the performance of PCR and IgM testing, we did report serologic positivity the same day as
255 positive molecular-based SARS-CoV-2 RNA detection, supporting its ability to detect antibody
256 response while viral shedding is still occurring. Furthermore, we found that measuring anti-
257 SARS-CoV-2 IgM and IgG on the same sample exhibits greater sensitivity than anti-SARS-
258 CoV-2 IgG testing alone, especially when measured on the same day as PCR positivity. While
259 anti-SARS-CoV-2 IgG assays exhibit good clinical performance, their greatest utility is seen two
260 weeks after symptom onset (23,25–27). For example, sensitivity of the Abbott SARS-CoV-2 IgG
261 assay was reported to reach 100% at day 17 after symptom onset (day 13 after PCR positivity)
262 when assessing 689 serum specimens (25) and to exhibit an overall sensitivity of 78.3%,
263 reaching 100% sensitivity 15 days after symptom onset when assessing 141 serum specimens
264 (26). We report a similar trend with Abbott SARS-CoV-2 IgG sensitivity 64.4% <14 days post-
265 PCR positivity and 82.4% \geq 14 days and DiaSorin anti-SARS-CoV-2 IgG sensitivity 52.1% <14
266 days and 80.4% \geq 14 days.

267 Our study reported 100% specificity for all four serologic assays using 52 samples
268 collected pre-COVID-19 or from PCR negative patients. Previous studies reported slightly lower
269 specificities with higher sample sizes. A meta-analysis reported overall specificity for anti-
270 SARS-CoV-2 IgG and IgM assays of 99.1% (44 studies included) and 98.7% (41 studies
271 included), respectively (9). Perkmann, et al. previously reported specificities of 99.2% for Abbott
272 anti-SARS-CoV-2 IgG, 98.3% for DiaSorin anti-SARS-CoV-2 IgG, and 99.7% for Roche anti-
273 SARS-CoV-2 total using over 1,154 pre-COVID-19 specimens (22). Other studies reported

274 specificities of 99.9% using 1,020 serum specimens collected prior to SARS-CoV-2 circulation
275 (25) and 99.3% using 107 serum specimens collected either before the emergence of SARS-
276 CoV-2 or from PCR negative patients (26) for Abbott anti-SARS-CoV-2 IgG.

277 The trend observed in anti-SARS-CoV-2 IgG (Abbott) index values measured in serial
278 samples over time were previously shown to vary among eight COVID-19 patients confirmed
279 with PCR positivity (25). Some patients reached the positivity threshold by 12 days post-
280 symptom onset, others plateaued after 12-16 days, while others continued to rise after 16 days
281 (25). One study of sixty-three patients with confirmed COVID-19 collected samples at 3-day
282 intervals until discharge and reported seroconversion in 96.8% of patients with the median time
283 to seroconversion of 13 days (12). Interestingly, three seroconversion types were observed:
284 synchronous IgG and IgM seroconversion, IgM seroconversion earlier than IgG, or IgM
285 seroconversion later than IgG (12). The trends observed in our study were similarly
286 heterogeneous between patients and the average time to seroconversion was 5.2, 2.2, 4.8, and 3.2
287 days post-PCR positivity for Abbott anti-SARS-CoV-2 IgG, Abbott anti-SARS-CoV-2 IgM,
288 DiaSorin anti-SARS-CoV-2 IgG, and Roche anti-SARS-CoV-2 total, respectively.

289 Our study is not without limitations. Firstly, we did not collect information on the day of
290 symptom onset due to confidentiality of personal health information, and thus all temporal data
291 is only depicted as days since PCR positivity. This limits the accuracy of our assessment of
292 sensitivity and antibody trends, as they are dependent on when the individual was tested for
293 SARS-CoV-2 infection by PCR. However, this measure does reduce the potential subjectivity of
294 using day of symptom onset as defined by each individual patient. Furthermore, as we did not
295 collect information on clinical presentation and/or symptom severity, we are unable to make

296 correlations between the assay signal and/or duration of antibody positivity with disease severity
297 and/or patient outcome.

298 In conclusion, we report a sensitivity of 87.5% 15-30 days post-PCR positivity, an overall
299 specificity of 100%, and no cross-reactivity with patient samples containing autoantibodies, viral
300 antigens, or viral antibodies for the Abbott anti-SARS-CoV-2 IgM assay. Combining Abbott
301 anti-SARS-CoV-2 IgM and IgG testing improved sensitivity by 22.7% compared to IgG testing
302 alone when tested the same day as PCR positivity. The Abbott anti-SARS-CoV-2 IgM assay
303 exhibited the earliest response and greatest signal in the majority of patients evaluated with serial
304 sampling and had the highest NPV <14 days post-PCR positivity, suggesting its potential utility
305 as an adjunct test to PCR early in disease course.

306 **Acknowledgements**

307 We would like to thank the UHN Core Lab Specimen Management team, Tech IVs, and
308 biochemists for their help with sample retrieval and input. VK serves as a consultant for Abbott
309 Diagnostics. DD and MB are employed by Abbott. Reagent kits were provided by Abbott
310 Diagnostics. This research received no specific grant from any funding agency in the public,
311 commercial, or not-for-profit sectors.

312

313

314

315

316

317

318

319 **References**

- 320 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients
321 with Pneumonia in China, 2019. *New England Journal of Medicine*. 2020 Feb
322 20;382(8):727–33.
- 323 2. Weekly Epidemiological Update: Coronavirus disease 2019 (COVID-19) [Internet]. World
324 Health Organization (WHO); 2020 [cited 2020 Oct 13]. Available from:
325 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201012-weekly-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201012-weekly-epi-update-9.pdf)
326 [epi-update-9.pdf](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201012-weekly-epi-update-9.pdf)
- 327 3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
328 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases
329 From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020
330 07;323(13):1239–42.
- 331 4. Carter LJ, Garner LV, Smoot JW, Li Y, Zhou Q, Saveson CJ, et al. Assay Techniques and
332 Test Development for COVID-19 Diagnosis. *ACS central science*. 2020 May 27;6(5):591–
333 605.
- 334 5. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2.
335 *JAMA*. 2020 Jun 9;323(22):2249–51.
- 336 6. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease
337 severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March
338 2020: retrospective cohort study. *BMJ (Clinical research ed)*. 2020 21;369:m1443.
- 339 7. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
340 Virological assessment of hospitalized patients with COVID-2019. *Nature*.
341 2020;581(7809):465–9.

- 342 8. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative
343 Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by
344 Time Since Exposure. *Ann Intern Med.* 2020 18;173(4):262–7.
- 345 9. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al.
346 Antibody tests for identification of current and past infection with SARS-CoV-2. *The*
347 *Cochrane Database of Systematic Reviews.* 2020 25;6:CD013652.
- 348 10. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early Humoral Response
349 to Diagnose Novel Coronavirus Disease (COVID-19). *Clin Infect Dis.* 2020 28;71(15):778–
350 85.
- 351 11. Wang P. Combination of serological total antibody and RT-PCR test for detection of
352 SARS-COV-2 infections. *Journal of Virological Methods.* 2020 Sep;283:113919.
- 353 12. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to
354 SARS-CoV-2 in patients with COVID-19. *Nature Medicine.* 2020;26(6):845–8.
- 355 13. Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, et al. Different longitudinal patterns of
356 nucleic acid and serology testing results based on disease severity of COVID-19 patients.
357 *Emerging Microbes & Infections.* 2020 Dec;9(1):833–6.
- 358 14. Kofler N, Baylis F. Ten reasons why immunity passports are a bad idea. *Nature.*
359 2020;581(7809):379–81.
- 360 15. Weinstein MC, Freedberg KA, Hyle EP, Paltiel AD. Waiting for Certainty on Covid-19
361 Antibody Tests - At What Cost? *N Engl J Med.* 2020 Aug 6;383(6):e37.
- 362 16. Ng DL, Goldgof GM, Shy BR, Levine AG, Balcerek J, Bapat SP, et al. SARS-CoV-2
363 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco
364 Bay Area. *medRxiv.* 2020 May 25;

- 365 17. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, et al. SARS-
366 CoV-2 infection protects against rechallenge in rhesus macaques. *Science*. 2020 Aug
367 14;369(6505):812–7.
- 368 18. Addetia A, Crawford KH, Dingens A, Zhu H, Roychoudhury P, Huang M, et al.
369 Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a
370 fishery vessel outbreak with high attack rate [Internet]. *Infectious Diseases (except*
371 *HIV/AIDS)*; 2020 Aug [cited 2020 Oct 16]. Available from:
372 <http://medrxiv.org/lookup/doi/10.1101/2020.08.13.20173161>
- 373 19. Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses:
374 Challenges and pitfalls. *Virus Research*. 2014 Dec;194:175–83.
- 375 20. Van Caesele P, Canadian Public Health Laboratory Network, Bailey D, Canadian Society
376 of Clinical Chemists, Forgie SE, Association of Medical Microbiology and Infectious
377 Disease Canada, et al. SARS-CoV-2 (COVID-19) serology: implications for clinical
378 practice, laboratory medicine and public health. *CMAJ*. 2020 24;192(34):E973–9.
- 379 21. Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui L-P, Johnston JC, et al.
380 Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis.
381 *BMJ*. 2020 01;370:m2516.
- 382 22. Perkmann T, Perkmann-Nagele N, Breyer M-K, Breyer-Kohansal R, Burghuber OC, Hartl
383 S, et al. Side by side comparison of three fully automated SARS-CoV-2 antibody assays
384 with a focus on specificity. *Clin Chem*. 2020 Aug 10;
- 385 23. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al.
386 Clinical Performance of the Roche SARS-CoV-2 Serologic Assay. *Clin Chem*. 2020
387 01;66(8):1107–9.

- 388 24. Suhandynata RT, Hoffman MA, Kelner MJ, McLawhon RW, Reed SL, Fitzgerald RL.
389 Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-
390 19. *J Appl Lab Med*. 2020 01;5(5):908–20.
- 391 25. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance
392 Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in
393 Boise, Idaho. *Journal of Clinical Microbiology*. 2020 23;58(8).
- 394 26. Nicol T, Lefeuvre C, Serri O, Pivert A, Joubaud F, Dubée V, et al. Assessment of SARS-
395 CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three
396 immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid
397 lateral flow immunoassay (NG Biotech). *Journal of Clinical Virology: The Official
398 Publication of the Pan American Society for Clinical Virology*. 2020;129:104511.
- 399 27. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al.
400 Clinical Performance of Two SARS-CoV-2 Serologic Assays. *Clin Chem*. 2020
401 01;66(8):1055–62.

402

403

404

405

406

407

408

409

410

411 **Figure Legends:**

412 **Fig. 1:** Anti-SARS-CoV-2 antibody results plotted against days since PCR positivity for four
413 SARS-CoV-2 serologic assays: **(A)** Abbott anti-SARS-CoV-2 IgG, **(B)** Abbott anti-SARS-CoV-
414 2 IgM, **(C)** DiaSorin anti-SARS-CoV-2 IgG, and **(D)** Roche anti-SARS-CoV-2 total. The solid
415 red horizontal line indicates the assay specific positivity cut-off.

416 **Fig. 2:** Total sensitivity and sensitivity for 0, 1-5, 6-14, 15-30, and >30 days since PCR positivity
417 for four Abbott anti-SARS-CoV-2 IgG, Abbott anti-SARS-CoV-2 IgM, Abbott anti-SARS-CoV-
418 2 IgG and IgM together (either assay is positive), DiaSorin anti-SARS-CoV-2 IgG, and Roche
419 anti-SARS-CoV-2 total

420 **Fig. 3:** **(A)** Anti-SARS-CoV-2 antibody response by days since PCR positivity in Patient 1 as
421 depicted by serial sampling. Data is plotted as a ratio of the response (i.e. assay signal) to the
422 positivity cut-off of the assay. This ratio is plotted against days since PCR positivity. **(B)**
423 Zoomed in view to better visualize the response around the positivity cut-off (i.e. ratio =1)

424 **Fig. 4:** **(A)** Anti-SARS-CoV-2 antibody response by days since PCR positivity in Patient 2 as
425 depicted by serial sampling. Data is plotted as a ratio of the response (i.e. assay signal) to the
426 positivity cut-off of the assay. This ratio is plotted against days since PCR positivity. **(B)**
427 Zoomed in view to better visualize the response around the positivity cut-off (i.e. ratio =1)

428 **Fig. 5:** **(A)** Anti-SARS-CoV-2 antibody response by days since PCR positivity in Patient 3 as
429 depicted by serial sampling. Data is plotted as a ratio of the response (i.e. assay signal) to the
430 positivity cut-off of the assay. This ratio is plotted against days since PCR positivity. **(B)**
431 Zoomed in view to better visualize the response around the positivity cut-off (i.e. ratio =1)

432 **Fig. 6:** **(A)** Anti-SARS-CoV-2 antibody response by days since PCR positivity in Patient 4 as
433 depicted by serial sampling. Data is plotted as a ratio of the response (i.e. assay signal) to the

434 positivity cut-off of the assay. This ratio is plotted against days since PCR positivity. **(B)**
435 Zoomed in view to better visualize the response around the positivity cut-off (i.e. ratio =1)
436 **Fig. 7: (A)** Anti-SARS-CoV-2 antibody response by days since PCR positivity in Patient 5 as
437 depicted by serial sampling. Data is plotted as a ratio of the response (i.e. assay signal) to the
438 positivity cut-off of the assay. This ratio is plotted against days since PCR positivity. **(B)**
439 Zoomed in view to better visualize the response around the positivity cut-off (i.e. ratio =1)
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456

457 **Table 1.** Sensitivity comparison among four SARS-CoV-2 serologic assays by days post-PCR
 458 positivity

	Total	Days Post-PCR Positivity						
		0	1-5	6-14	15-30	>30	<14	≥14
n	175	22	17	38	54	44	73	102
Abbott IgG	74.9%	40.9%	76.5%	76.3%	85.2%	77.3%	64.4%	82.4%
Abbott IgM	74.3%	63.6%	76.5%	76.3%	85.2%	63.6%	71.2%	76.5%
DiaSorin IgG^a	69.0%	38.1%	52.9%	65.8%	83.3%	75.0%	52.1%	80.4%
Roche Total^b	73.6%	45.5%	70.6%	71.1%	83.3%	79.1%	61.6%	81.4%

459 *Sensitivity calculated as true positive / (true positive + false negative), with a true positive determine by
 460 PCR positivity

461 ^aSample size for DiaSorin IgG was 174. (n=72 for Day <14; n=21 for Day 0)

462 ^bSample size for Roche Total was 174. (n-101 for Day ≥14; n=43 for Day >30)

463
 464 **Table 2.** Sensitivity comparison among Abbott IgM and Abbott IgG anti-SARS-CoV-2 serologic
 465 assays by days post-PCR positivity

	Total	Days Post-PCR Positivity						
		0	1-5	6-14	15-30	>30	<14	≥14
n	175	22	17	38	54	44	73	102
Total Abbott IgG	74.9%	40.9%	76.5%	76.3%	85.2%	77.3%	64.4%	82.4%
Total Abbott IgM	74.3%	63.6%	76.5%	76.3%	85.2%	63.6%	71.2%	76.5%
Abbott IgM and IgG	71.4%	40.9%	76.5%	76.3%	85.2%	63.6%	64.4%	76.5%
Abbott IgM or IgG	77.7%	63.6%	76.5%	76.3%	85.2%	77.3%	71.2%	82.4%
Abbott IgG Only	3.4%	0.0%	0.0%	0.0%	0.0%	13.6%	0.0%	5.9%
Abbott IgM Only	2.9%	22.7%	0.0%	0.0%	0.0%	0.0%	6.8%	0.0%

466 *Sensitivity calculated as true positive / (true positive + false negative), with a true positive determine by
 467 PCR positivity

468
 469
 470
 471

472 **Table 3.** Concordance between four anti-SARS-CoV-2 serologic assays

	n	Overall Agreement (%)	PPA (%)	NPA (%)	Cohen's Kappa
Abbott IgG – Abbott IgM	282	95.7	94.7	96.7	0.91
Abbott IgG – DiaSorin IgG	281	95.0	90.2	99.3	0.90
Abbott IgG – Roche Total	281	96.4	94.7	98.0	0.93
Abbott IgM – DiaSorin IgG	281	93.2	89.1	96.7	0.86
Abbott IgM – Roche Total	281	94.3	93.1	95.4	0.89
DiaSorin IgG – Roche Total	280	94.6	96.7	93.1	0.89

473 NPA, negative percent agreement, PPA, positive percent agreement

474

475 **Table 4.** Days from PCR positivity to seroconversion

	Abbott IgG	Abbott IgM	DiaSorin IgG	Roche Total
Patient 1	2	0	3	2
Patient 2	3	0	3	2
Patient 3	11	11	14	11
Patient 4	7	0	2	0
Patient 5	3	0	2	1
Median (IQR)	3 (3-7)	0 (0-0)	3 (2-3)	2 (1-2)
Mean (SD)	5.2 (3.8)	2.2 (4.9)	4.8 (5.2)	3.2 (4.4)

476 *Seroconversion defined as first day of antibody positivity.

477 IQR, interquartile range; SD, standard deviation

478

479

480

481

482

483

484

485

486

487 **Table 5.** Positive and negative predictive values at 1%, 5%, and 10% seroprevalence for four
 488 anti-SARS-CoV-2 serologic assays

		Abbott IgG	Abbott IgM	DiaSorin IgG	Roche Total
<14 Days Post-PCR Positivity					
Sensitivity		64.4%	71.2%	52.1%	61.6%
Specificity		100%	100%	100%	100%
Seroprevalence					
1%	PPV	100%	100%	100%	100%
	NPV	99.6%	99.7%	99.5%	99.6%
5%	PPV	100%	100%	100%	100%
	NPV	98.3%	98.6%	97.7%	98.1%
10%	PPV	100%	100%	100%	100%
	NPV	96.6%	97.2%	95.4%	96.3%
≥14 Days Post-PCR Positivity					
Sensitivity		82.4%	76.5%	80.4%	81.4%
Specificity		100%	100%	100%	100%
Seroprevalence					
1%	PPV	100%	100%	100%	100%
	NPV	99.8%	99.8%	99.8%	99.8%
5%	PPV	100%	100%	100%	100%
	NPV	99.1%	98.8%	99.0%	99.1%
10%	PPV	100%	100%	100%	100%
	NPV	98.3%	97.7%	98.1%	98.2%

489 *Sensitivity and specificity for each serologic assay was determined in this study.

490 NPV, negative predictive value; PPV, positive predictive value







Fig. 1




Fig. 2





Fig. 3





Fig. 4





Fig. 5





Fig. 6





Fig. 7